AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38969879 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab cohort (n=27)
Number of subjects: 97
Study 38969879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin cohort (n=26)
Number of subjects: 97
Study 38969921 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L
Number of subjects: 612
Study 38969921 — intervention group
Group type: EXPERIMENTAL
Intervention: AAPPO
Number of subjects: 612
Study 38969921 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36v2
Number of subjects: 612
Study 38969921 — intervention group
Group type: EXPERIMENTAL
Intervention: SALT
Number of subjects: 612
Study 38969921 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI-C
Number of subjects: 612
Study 38969919 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan 5 mg/1.5 mL
Number of subjects: 33
Study 38969919 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan 10 mg/1.5 mL
Number of subjects: 33
Study 38969919 — intervention group
Group type: COMPARATOR
Intervention: Somapacitan 5 mg/1.5 mL and Somapacitan 10 mg/1.5 mL
Number of subjects: 33
Study 38969987 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component implementation strategies including identifying clinic champions, development/distribution of patient educational materials, developing and implementing quality monitoring systems, and convening clinical meetings.
Number of subjects: 180
Study 38970004 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional open-tray impressions CII (splinted pick-up)
Number of subjects: 8
Study 38970004 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital implant impressions DII with TRIOS 3 Shape intraoral scanner
Number of subjects: 8
Study 38970008 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherogenic index of plasma (AIP) calculated as log10 (TG/HDL)
Number of subjects: 585
Study 38970008 — intervention group
Group type: EXPERIMENTAL
Intervention: AIP as a predictor of GDM
Number of subjects: 585
Study 38970037 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time ambulatory assessments using a wrist-worn actigraphy device and electronic ecological momentary assessment for perceived discrimination, microaggression, and stress.
Number of subjects: 80
Study 38970037 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous blood pressure monitoring through a wristband.
Number of subjects: 80
Study 38970037 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected saliva samples for cortisol level assessment.
Number of subjects: 80
Study 38970037 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting venous blood sample for lab assessments.
Number of subjects: 80
Study 38970037 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood-level built environmental and social environmental characteristics based on participants' addresses.
Number of subjects: 80
Study 38970065 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 0
Study 38970065 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycoside + Ciprofloxacin
Number of subjects: 0
Study 38970070 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-informed platform for health intervention
Number of subjects: 120
Study 38970127 — intervention group
Group type: EXPERIMENTAL
Intervention: Posiphen 60 mg once/day
Number of subjects: 19
Study 38970127 — intervention group
Group type: EXPERIMENTAL
Intervention: Posiphen 60 mg twice/day
Number of subjects: 19
Study 38970127 — intervention group
Group type: EXPERIMENTAL
Intervention: Posiphen 60 mg three times/day
Number of subjects: 19
Study 38970127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 38970237 — intervention group
Group type: EXPERIMENTAL
Intervention: Gunshot wounds
Number of subjects: 163
Study 38970237 — intervention group
Group type: COMPARATOR
Intervention: Bomb blast wounds
Number of subjects: 163
Study 38970256 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib 60 mg twice daily + Temozolomide (TMZ) 60 mg once daily pulsed (7-day schedule)
Number of subjects: 139
Study 38970256 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib + TMZ
Number of subjects: 139
Study 38970327 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3 co-administered with FLU-D-QIV
Number of subjects: 1415
Study 38970327 — intervention group
Group type: COMPARATOR
Intervention: FLU-D-QIV alone
Number of subjects: 1415
Study 38970327 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of RSVPreF3 and FLU-D-QIV
Number of subjects: 1415
Study 38970425 — intervention group
Group type: EXPERIMENTAL
Intervention: Timrepigene emparvovec (gene therapy), up to 0.1 mL containing 1 × 10^11 vg/mL, administered bilaterally and sequentially.
Number of subjects: 0
Study 38970585 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary antegrade wiring (AW)
Number of subjects: 12136
Study 38970585 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme gradient boosting machine learning model
Number of subjects: 12136
Study 38970587 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapy (GDMT)
Number of subjects: 400
Study 38970593 — intervention group
Group type: EXPERIMENTAL
Intervention: RF-CL model
Number of subjects: 4371
Study 38970593 — intervention group
Group type: EXPERIMENTAL
Intervention: CACS-CL model
Number of subjects: 4371
Study 38970593 — intervention group
Group type: COMPARATOR
Intervention: Basic PTP model
Number of subjects: 4371
Study 38970593 — intervention group
Group type: EXPERIMENTAL
Intervention: RF-CL and CACS-CL models
Number of subjects: 4371
Study 38970665 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised nutrition feedback based on new sustainable healthy eating guidelines
Number of subjects: 20
Study 38970665 — intervention group
Group type: COMPARATOR
Intervention: Existing healthy eating guidelines (control)
Number of subjects: 20
Study 38970708 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI training protocol (customized booklet, MRI toy set, mock scanner)
Number of subjects: 57
Study 38970708 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental assessments (MABC, TVIP, ABAS, BRIEF, CBCL, NIH Toolbox Flanker, NIH Toolbox Pattern Comparison, WPPSI)
Number of subjects: 57
Study 38970713 — intervention group
Group type: EXPERIMENTAL
Intervention: No abdominal drain and no prolonged antibiotic prophylaxis
Number of subjects: 36
Study 38970713 — intervention group
Group type: COMPARATOR
Intervention: Abdominal drain and prolonged antibiotic prophylaxis
Number of subjects: 36
Study 38970713 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical right colectomy (RRC)
Number of subjects: 36
Study 38970713 — intervention group
Group type: COMPARATOR
Intervention: Standard D2 dissection
Number of subjects: 36
Study 38971151 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant monotherapy with the PARP inhibitor (PARPi) niraparib
Number of subjects: 100
Study 38971151 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapies
Number of subjects: 100
Study 38971175 — intervention group
Group type: EXPERIMENTAL
Intervention: BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone)
Number of subjects: 1482
Study 38971175 — intervention group
Group type: COMPARATOR
Intervention: eBEACOPP
Number of subjects: 1482
Study 38971202 — intervention group
Group type: EXPERIMENTAL
Intervention: DBIP-ESD
Number of subjects: 140
Study 38971202 — intervention group
Group type: COMPARATOR
Intervention: T-ESD
Number of subjects: 140
Study 38971385 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized response-based adaptive radiation therapy (RT) with concurrent chemoradiation therapy
Number of subjects: 47
Study 38971385 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized response-based adaptive radiation therapy (RT)
Number of subjects: 47
Study 38971424 — intervention group
Group type: EXPERIMENTAL
Intervention: Pecan-containing meal
Number of subjects: 0
Study 38971424 — intervention group
Group type: COMPARATOR
Intervention: Energy- and macronutrient-matched control meal
Number of subjects: 0
Study 38971633 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil
Number of subjects: 86
Study 38971633 — intervention group
Group type: COMPARATOR
Intervention: Silicone-based spray
Number of subjects: 86
Study 38971713 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital guideline support
Number of subjects: 204
Study 38971713 — intervention group
Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 204
Study 38971713 — intervention group
Group type: COMPARATOR
Intervention: Expert approach
Number of subjects: 204
Study 38971743 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk management program including professional e-learning training, identification of a risk management advisor, and multidisciplinary meetings.
Number of subjects: 401
Study 38971743 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention).
Number of subjects: 401
Study 38971756 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line filtration
Number of subjects: 736
Study 38971756 — intervention group
Group type: COMPARATOR
Intervention: Control (no in-line filtration)
Number of subjects: 736
Study 38971950 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg twice daily
Number of subjects: 0
Study 38971950 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg on Day 1 every 3 weeks
Number of subjects: 0
Study 38971950 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib plus Atezolizumab
Number of subjects: 0
Study 38972091 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Brain Initiative care bundle (SBI-CB) including 18 delirium-reducing recommendations, patient education, staff training, coordination meetings, and outcome monitoring in the PACU.
Number of subjects: 18697
Study 38972091 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial POD incidence in the PACU after the first three months was 16.36% (n = 1021).
Number of subjects: 18697
Study 38972306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric Citrate (FC)
Number of subjects: 209
Study 38972306 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 209
Study 38972465 — intervention group
Group type: EXPERIMENTAL
Intervention: SBPT (38 Gy in 5 fractions)
Number of subjects: 135
Study 38972465 — intervention group
Group type: COMPARATOR
Intervention: CFPT (79.2 Gy in 44 fractions)
Number of subjects: 135
Study 38972465 — intervention group
Group type: EXPERIMENTAL
Intervention: SBPT
Number of subjects: 135
Study 38972465 — intervention group
Group type: COMPARATOR
Intervention: SBPT and CFPT
Number of subjects: 135
Study 38972535 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI heparin
Number of subjects: 4088
Study 38972535 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hourly dose or total doses of heparin
Number of subjects: 4088
Study 38972535 — intervention group
Group type: COMPARATOR
Intervention: No post-PCI heparin
Number of subjects: 4088
Study 38972612 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (400 mg dose)
Number of subjects: 15
Study 38972612 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily consumption of 2 × 400 mg of nitrate over 4 weeks
Number of subjects: 15
Study 38972612 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nitrate-depleted beetroot juice)
Number of subjects: 15
Study 38972617 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged and repeated microemboli detection using bilateral stationary TCDM for one hour followed by unilateral ambulatory TCDM for two hours, repeated for two days and after three months
Number of subjects: 47
Study 38972617 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial microemboli detection
Number of subjects: 47
Study 38972617 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged and repeated microemboli detection
Number of subjects: 47
Study 38972831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive prostatectomy with systemic therapy
Number of subjects: 352
Study 38972831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive prostate radiotherapy or ablation with systemic therapy
Number of subjects: 352
Study 38972831 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional cytoreductive treatment
Number of subjects: 352
Study 38972960 — intervention group
Group type: EXPERIMENTAL
Intervention: CF-LI-guided pulmonary vein isolation (PVI)
Number of subjects: 275
Study 38972960 — intervention group
Group type: EXPERIMENTAL
Intervention: CF-LI-guided PVI
Number of subjects: 275
Study 38972988 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined program of physical exercise and cognitive training (experimental group, EG)
Number of subjects: 95
Study 38972988 — intervention group
Group type: COMPARATOR
Intervention: Cognitive stimulation (control group, CG)
Number of subjects: 95
Study 38973149 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (n=23)
Number of subjects: 205
Study 38973149 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers (n=92)
Number of subjects: 205
Study 38973149 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (RA patients, n=38)
Number of subjects: 205
Study 38973793 — intervention group
Group type: EXPERIMENTAL
Intervention: Coil localization
Number of subjects: 100
Study 38973793 — intervention group
Group type: EXPERIMENTAL
Intervention: Anchored needle (AN) localization
Number of subjects: 100
Study 38974112 — intervention group
Group type: EXPERIMENTAL
Intervention: Training using the SBAR/SAED tool and standard instructions for managing respiratory distress/dyspnea
Number of subjects: 0
Study 38974112 — intervention group
Group type: COMPARATOR
Intervention: Standard instructions only
Number of subjects: 0
Study 38974350 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral thiamine (100 mg daily for ≥3 d)
Number of subjects: 287
Study 38974350 — intervention group
Group type: COMPARATOR
Intervention: Community comparison group (matched by age, sex, and residence)
Number of subjects: 287
Study 38974350 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine biomarkers
Number of subjects: 287
Study 38974350 — intervention group
Group type: EXPERIMENTAL
Intervention: ThDP
Number of subjects: 287
Study 38974656 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38974817 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory pulmonary venous volume
Number of subjects: 138
Study 38974817 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) quantitative pulmonary vessel morphology
Number of subjects: 138
Study 38974920 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization Breakdown Interview (MBI-RF)
Number of subjects: 45
Study 38974920 — intervention group
Group type: COMPARATOR
Intervention: Adult Attachment Interview (AAI-RF)
Number of subjects: 45
Study 38974920 — intervention group
Group type: EXPERIMENTAL
Intervention: MBI-RF
Number of subjects: 45
Study 38974920 — intervention group
Group type: COMPARATOR
Intervention: AAI-RF
Number of subjects: 45
Study 38974930 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)
Number of subjects: 20
Study 38975122 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study 38975302 — intervention group
Group type: EXPERIMENTAL
Intervention: l-oxiracetam
Number of subjects: 590
Study 38975302 — intervention group
Group type: EXPERIMENTAL
Intervention: oxiracetam
Number of subjects: 590
Study 38975302 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 590
Study 38975624 — intervention group
Group type: EXPERIMENTAL
Intervention: valoctocogene roxaparvovec
Number of subjects: 2
Study 38975711 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tyrosine (2000 mg)
Number of subjects: 80
Study 38975711 — intervention group
Group type: EXPERIMENTAL
Intervention: L-theanine (200 mg)
Number of subjects: 80
Study 38975711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 38976019 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 45
Study 38976019 — intervention group
Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 45
Study 38976035 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA-targeted positron emission tomography (PET-CT)
Number of subjects: 20
Study 38976035 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care imaging (CT/bone scan)
Number of subjects: 20
Study 38976096 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC transfusion
Number of subjects: 63
Study 38976126 — intervention group
Group type: EXPERIMENTAL
Intervention: SB11 Pre-filled Syringe (PFS) administered at a dosage of 0.5 mg via intravitreal injection (IVT).
Number of subjects: 34
Study 38976265 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-mg dose of a weekly extended-release formulation of buprenorphine (CAM2038)
Number of subjects: 100
Study 38976270 — intervention group
Group type: EXPERIMENTAL
Intervention: VMP 200 mg twice a day
Number of subjects: 129
Study 38976270 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 129
Study 38976270 — intervention group
Group type: EXPERIMENTAL
Intervention: VMP 200 mg twice a day (twin pregnancies)
Number of subjects: 129
Study 38976270 — intervention group
Group type: COMPARATOR
Intervention: No treatment (twin pregnancies)
Number of subjects: 129
Study 38976321 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental app with additional content tailored for PAQS and those with HIV
Number of subjects: 19
Study 38976321 — intervention group
Group type: COMPARATOR
Intervention: Standard care control app
Number of subjects: 19
Study 38976363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilofexor 30 mg (weeks 1-4), 60 mg (weeks 5-8), 100 mg (weeks 9-12)
Number of subjects: 11
Study 38976448 — intervention group
Group type: EXPERIMENTAL
Intervention: Zastaprazan 20 mg once daily for 8 weeks
Number of subjects: 300
Study 38976448 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg once daily for 8 weeks
Number of subjects: 300
Study 38976448 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300
Study 38976481 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal Mindfulness Training
Number of subjects: 0
Study 38976481 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38976607 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention details not available
Number of subjects: 0
Study 38976641 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions that support the sharing of information on HIV among OPWH and caregivers
Number of subjects: 29
Study 38976708 — intervention group
Group type: EXPERIMENTAL
Intervention: People with obesity and schizophrenia
Number of subjects: 80
Study 38976708 — intervention group
Group type: EXPERIMENTAL
Intervention: People with obesity and bipolar disorder
Number of subjects: 80
Study 38976708 — intervention group
Group type: COMPARATOR
Intervention: People with obesity without mental disease or sleep disorders
Number of subjects: 80
Study 38976708 — intervention group
Group type: COMPARATOR
Intervention: People without obesity, mental disease or sleep disorders
Number of subjects: 80
Study 38976710 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic exoskeleton intervention for 12 weeks
Number of subjects: 0
Study 38976710 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy for 12 weeks
Number of subjects: 0
Study 38976993 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine-test counselling group
Number of subjects: 100
Study 38976993 — intervention group
Group type: COMPARATOR
Intervention: Standard of care group
Number of subjects: 100
Study 38977179 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling kit (SSK) offered by GP during consultation (Arm A)
Number of subjects: 3375
Study 38977179 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling kit (SSK) sent with a personal GP signed invitation letter (Arm B)
Number of subjects: 3375
Study 38977179 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation letter from the Centre for Cancer Detection (Control Arm)
Number of subjects: 3375
Study 38977179 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling kit (SSK) offered by GP (Arm A)
Number of subjects: 3375
Study 38977276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ) 160 mg
Number of subjects: 586
Study 38977276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study 38977276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ) in patients with history of uveitis
Number of subjects: 586
Study 38977276 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with history of uveitis
Number of subjects: 586
Study 38977276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ) in phase 2b/3 pool
Number of subjects: 586
Study 38977298 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine (3+1 schedule)
Number of subjects: 129
Study 38977298 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine (2+1 schedule)
Number of subjects: 129
Study 38977361 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace treatment with a Pavlik harness for a minimum of 6 weeks
Number of subjects: 514
Study 38977361 — intervention group
Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 514
Study 38977368 — intervention group
Group type: EXPERIMENTAL
Intervention: COACH intervention with enhanced alerts and displays
Number of subjects: 0
Study 38977368 — intervention group
Group type: COMPARATOR
Intervention: COACH without alerts and a simple display (Control)
Number of subjects: 0
Study 38977430 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 147
Study 38977536 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy and 20 mg of oral rosuvastatin once daily for 6 months
Number of subjects: 50
Study 38977536 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy (control group)
Number of subjects: 50
Study 38977651 — intervention group
Group type: EXPERIMENTAL
Intervention: ECAP dose-controlled closed-loop spinal cord stimulation (SCS)
Number of subjects: 132
Study 38977651 — intervention group
Group type: COMPARATOR
Intervention: Day 0 evaluation
Number of subjects: 132
Study 38977653 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 0
Study 38977653 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 0